Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00004856
Other study ID # NCI-2011-02046
Secondary ID CALGB 90101UCSF-
Status Terminated
Phase Phase 2
First received March 7, 2000
Last updated May 1, 2013
Start date July 2002

Study information

Verified date May 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.


Description:

OBJECTIVES:

I. Determine the response rate in patients with previously treated, locally advanced or metastatic transitional cell carcinoma of the urothelium treated with trastuzumab (Herceptin).

II. Determine the safety of this drug in this patient population. III. Determine overall and progression-free survival of this patient population treated with this drug.

OUTLINE:

Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.

Patients are followed every 3 months for 1 year and then every 6 months thereafter.


Recruitment information / eligibility

Status Terminated
Enrollment 40
Est. completion date
Est. primary completion date July 2002
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed transitional cell carcinoma (TCC) of the urothelium, including the bladder, urethra, ureter, or renal pelvis

- No pure adenocarcinomas, pure squamous cell carcinomas, small cell carcinoma, or only small foci of TCC (less than 10% of tumor specimen)

- Locally advanced (T4b) TCC of the bladder

- Metastatic (N2 or N3 or M1)TCC of the urothelium

- HER2 expression (3+) as determined by immunohistochemistry or gene amplification by fluorescent in situ hybridization

- Must not be a candidate for potentially curative surgery or radiotherapy

- Measurable disease

- At least 1 unidimensionally measurable lesion of at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

- The following lesions are considered nonmeasurable:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Lymphangitis cutis/pulmonis

- Abdominal masses not confirmed and followed by imaging techniques

- Cystic lesions

- Primary bladder masses

- Relapsed from or failed to achieve a complete or partial response after 1 prior systemic chemotherapy regimen for TCC, including cisplatin, carboplatin, paclitaxel, docetaxel, or gemcitabine

- Prior adjuvant or neoadjuvant chemotherapy is considered 1 prior chemotherapy regimen

- Prior single-agent chemotherapy as a radiosensitizer is not considered a prior systemic chemotherapy regimen

- No known brain metastases

- Performance status - CTC 0-2

- More than 12 weeks

- Absolute neutrophil count at least 1,000/mm^3

- Platelet count at least 75,000/mm^3

- Bilirubin no greater than 2 times upper limit of normal (ULN)

- AST no greater than 2 times ULN

- Creatinine clearance at least 30 mL/min

- Ejection fraction at least 50% (or lower limit of normal) by echocardiogram or MUGA

- No history of ongoing congestive heart failure

- No active cardiac ischemia

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

- HIV negative

- No known autoimmune disease

- No prior trastuzumab (Herceptin)

- At least 14 days since prior radiotherapy

- At least 30 days since prior chemotherapy

- Prior doxorubicin allowed provided cumulative dose is no greater than 300 mg/m^2

- Prior epirubicin allowed provided cumulative dose is no greater than 600 mg/m^2

- No concurrent chemotherapy

- No concurrent hormonal therapy except:

- Steroids given for adrenal failure

- Hormones administered for nondisease-related conditions (e.g., insulin for diabetes)

- Intermittent dexamethasone as an antiemetic or for sensitivity reactions to study drug

- No concurrent palliative radiotherapy

- Prior radiotherapy allowed provided treated area is not only site of measurable disease

- At least 14 days since prior surgery

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
trastuzumab
Given IV

Locations

Country Name City State
United States Cancer and Leukemia Group B Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (complete or partial response) as assessed by RECIST criteria 1 year No
Secondary Toxicities as graded according to the NCI Common Toxicity Criteria 12 weeks Yes
Secondary Proportion of patients who are HER2 positive (3+ by IHC or FISH positive) Baseline No
Secondary Overall survival (OS) From date of initiation of treatment to date of death due to any cause, assessed up to 1 year No
Secondary Disease-free survival (DFS) From date of initiation of treatment to date of progression or death due to any cause, whichever occurs first, assessed up to 1 year No
See also
  Status Clinical Trial Phase
Terminated NCT02122172 - Afatinib in Advanced Refractory Urothelial Cancer Phase 2
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01938573 - Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Phase 1/Phase 2
Terminated NCT00112905 - Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Phase 2
Completed NCT00072150 - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Phase 2
Terminated NCT00072137 - Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Phase 1
Completed NCT00028756 - Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Phase 3
Completed NCT00407485 - VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2
Terminated NCT00003452 - Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder Phase 2
Completed NCT00003167 - Gene Therapy in Treating Patients With Advanced Bladder Cancer Phase 1
Completed NCT00005831 - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Phase 2
Completed NCT00021099 - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Phase 2
Terminated NCT01382706 - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Phase 2
Active, not recruiting NCT04267575 - Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites N/A
Terminated NCT01954173 - Adjuvant Radiation for High Risk Bladder Cancer N/A
Active, not recruiting NCT04670445 - Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer N/A
Terminated NCT01282333 - Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer Phase 1
Completed NCT01828736 - Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma Phase 2
Terminated NCT02316548 - Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer Phase 2